Surgery Partners Inc (SGRY)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $3.53B
Last updated: Nov 17, 2026 at 4:10 PM ET
Surgery Partners Inc (SGRY) Statistics
Surgery Partners (SGRY) has a market cap of $3.53B and an enterprise value of $6.23B. Its trailing P/E of 95.9x is above its 5-year median of 34.1x. Its net debt of $2.70B equals 76.57% of its market cap.
Total Valuation
Enterprise value is 76.57% above the market cap, as debt exceeds cash.
| Market Cap | $3.53B |
|---|---|
| Enterprise Value | $6.23B |
| Latest price (Nov 17, 2026) | $26.85 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.0x and 2.1x. Its year-end P/E ranged from 22.5x to 214.3x from 2016 to 2025.
| P/E Ratio | 95.9x |
|---|---|
| Forward P/E | 66.2x |
| P/S Ratio | 1.0x |
| Forward P/S | 1.1x |
| P/B Ratio | 2.1x |
| P/FCF Ratio | 17.1x |
| P/OCF Ratio | 12.7x |
| PEG Ratio | 5.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 11.4x EBITDA and 30.4x free cash flow.
| EV / Earnings | 88.1x |
|---|---|
| EV / Sales | 1.9x |
| EV / EBITDA | 11.4x |
| EV / EBIT | 17.1x |
| EV / FCF | 30.4x |
Price Statistics
The stock is up 75.72% over 52 weeks and trades 50.76% above its 50-day average.
| Beta (1Y) | 1.02 |
|---|---|
| 52-Week Change | +75.72% |
| 1-Month Change | +82.53% |
| 3-Month Change | +97.43% |
| 6-Month Change | +96.13% |
| 5-Year Change | -43.58% |
| 10-Year Change | +44.16% |
| Total Return (1Y) | +75.72% |
| Total Return (3Y CAGR) | -5.91% |
| Total Return (5Y CAGR) | -11.43% |
| Return vs SPY (1Y) | +65.32% |
| Max Drawdown (1Y) | -34.00% |
| Max Drawdown (3Y) | -67.64% |
| Sharpe Ratio (1Y) | 0.94 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $17.81 |
| 200-Day Average | $15.21 |
| 52-Week Range | $11.41 to $27.23 |
| RSI (14 Days) | 87.8 |
| Average Volume (20 Days) | 7.59M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.17x current liabilities, and total debt is 1.84x shareholder equity.
| Current Ratio | 2.17x |
|---|---|
| Quick Ratio | 2.01x |
| Debt / Equity | 1.84x |
| Debt / EBITDA | 5.65x |
| Debt / FCF | 15.07x |
Returns and Efficiency
Return on invested capital is 6.10% over the last 12 months, against a 5-year average of 5.96%.
| Return on Equity (ROE) | 4.25% |
|---|---|
| Return on Assets (ROA) | 1.00% |
| Return on Invested Capital (ROIC) | 6.10% |
| Return on Capital Employed (ROCE) | 5.55% |
| ROE (5Y Average) | 4.83% |
| ROA (5Y Average) | 1.16% |
| ROIC (5Y Average) | 5.96% |
| Asset Turnover | 0.45x |
| Inventory Turnover | 9.43x |
| Receivables Turnover | 6.20x |
| Cash Conversion Cycle | 28 days |
Taxes
Income tax took 20.83% of pretax income over the last 12 months.
| Income Tax (TTM) | $18.60M |
|---|---|
| Effective Tax Rate | 20.83% |
Scores
SGRY has an Altman Z-Score of 1.12, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.12 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $3.36B over the last 12 months is up 2.19% from the 12 months before.
| Revenue | $3.36B |
|---|---|
| Revenue Growth (YoY) | +2.19% |
| Gross Profit | $2.53B |
| Operating Income | $363.70M |
| Pretax Income | $89.30M |
| Net Income | $70.70M |
| EBITDA | $541.00M |
| EBIT | $363.70M |
| Reported EPS (TTM) | $0.28 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 23.55% of the $7.05B in total assets.
| Cash and Equivalents | $354.50M |
|---|---|
| Total Debt | $3.06B |
| Net Debt | $2.70B |
| Net Debt Per Share | $20.96 |
| Working Capital | $581.40M |
| Shareholder Equity | $1.66B |
| Book Value Per Share | $12.92 |
| Tangible Book Value | -$2.98B |
| Total Assets | $7.05B |
| Total Liabilities | $3.79B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $75.10M of capital spending, operating cash flow left $202.80M of free cash flow.
| Operating Cash Flow | $277.90M |
|---|---|
| Capital Expenditures | $75.10M |
| Free Cash Flow | $202.80M |
| FCF Per Share | $1.57 |
| Depreciation and Amortization | $177.30M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 10.82%, against a 5-year average of 12.42%.
| Gross Margin | 75.26% |
|---|---|
| Operating Margin | 10.82% |
| Pretax Margin | 2.66% |
| Net Margin | 2.10% |
| EBITDA Margin | 16.10% |
| EBIT Margin | 10.82% |
| FCF Margin | 6.04% |
| Gross Margin (5Y Average) | 46.31% |
| Operating Margin (5Y Average) | 12.42% |
| Net Margin (5Y Average) | 2.99% |
Growth
Revenue grew 9.22% a year over 3 years, and EPS 52.38% a year.
| Revenue Growth (3Y CAGR) | +9.22% |
|---|---|
| Revenue Growth (5Y CAGR) | +12.21% |
| EPS Growth (3Y CAGR) | +52.38% |
| FCF Growth (3Y CAGR) | +35.74% |
| FCF Growth (5Y CAGR) | -0.84% |
| Operating Income Growth (3Y CAGR) | +4.11% |
| Book Value Per Share Growth (2Y CAGR) | -7.68% |
Dividends and Yields
SGRY does not pay a dividend. Its free cash flow yield is 5.86%.
| Earnings Yield | 1.04% |
|---|---|
| FCF Yield | 5.86% |
| Shareholder Yield | 6.25% |
Peer Position
Against 10 similar companies, SGRY has the highest P/E.
P/E RatioPeer median 22.7x
P/S RatioPeer median 1.7x
ROICPeer median 8.68%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +11.02%
| P/E Ratio | 95.9x vs 22.7x median |
|---|---|
| P/S Ratio | 1.0x vs 1.7x median |
| ROIC | 6.10% vs 8.68% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +2.19% vs +11.02% median |
Analyst Forecast
Consensus estimates put revenue growth at -6.06% and EPS growth at -34.05% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -6.06% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -34.05% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About SGRY
What is SGRY's market cap?
Surgery Partners has a market cap of $3.53B. Its enterprise value, which adds debt and subtracts cash, is $6.23B.
What is SGRY's P/E ratio?
Surgery Partners has a trailing P/E ratio of 95.9x and a forward P/E of 66.2x.
How many shares of SGRY are outstanding?
Surgery Partners has 128.87M shares outstanding. The count is up 1.30% from a year earlier.
Does SGRY pay a dividend?
No. Surgery Partners does not pay a dividend.
How much debt does SGRY have?
Surgery Partners has $3.06B of total debt and $354.50M of cash and equivalents, a net debt position of $2.70B.
SGRY pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors